If you or someone you love is struggling with treatment-resistant depression, you’ve probably started looking into every available option. Spravato has been generating a lot of attention lately, and for good reason. Clinical trials show the Spravato success rate is high – up to 80% of patients with treatment-resistant depression achieve a meaningful response to Spravato, with around 30-50% reaching full remission. Those numbers are significant, especially for a population that has already failed two or more antidepressant treatments. The success rate isn’t a guarantee, but for many patients, Spravato represents a real turning point.
Spravato Success Rate: What the Research Actually Says
If you or someone you love is struggling with treatment-resistant depression, you’ve probably started looking into every available option. Spravato has been generating a lot of attention lately, and for good reason. Clinical trials show the Spravato success rate is high – up to 80% of patients with treatment-resistant depression achieve a meaningful response to Spravato, with around 30-50% reaching full remission. Those numbers are significant, especially for a population that has already failed two or more antidepressant treatments. The success rate isn’t a guarantee, but for many patients, Spravato represents a real turning point.
Spravato is the brand name for esketamine, a chemical cousin of the anesthetic ketamine. Unlike traditional antidepressants that target serotonin or norepinephrine systems over weeks or months, the esketamine nasal spray works on the glutamate system – the brain’s most abundant neurotransmitter network. This different mechanism of action is why it can produce results far more quickly, sometimes within hours of the first dose.
The drug is self-administered under clinical supervision, meaning patients come to a certified healthcare setting, use the nasal spray themselves, and remain monitored for at least 2 hours. It’s typically prescribed alongside an oral antidepressant, not as a standalone therapy.
The FDA first approved Spravato in March 2019 for treatment-resistant depression in adults, and then expanded that approval later to cover major depressive disorder with acute suicidal ideation or behavior. This made it the first genuinely new class of fast-acting antidepressant to receive federal clearance in decades.
Not everyone with depression is a candidate for Spravato. The drug is specifically indicated for adults who have been diagnosed with major depressive disorder and have not responded adequately to at least two different oral antidepressants. This is the clinical definition of treatment-resistant depression (TRD), and it affects an estimated 30% of people living with depression.
Candidates may also qualify if they are experiencing:
Active suicidal thoughts or behaviors alongside a depressive episode
A history of multiple failed antidepressant trials over the years
Significant functional impairment due to ongoing depression
Co-occurring anxiety disorders that have complicated treatment
The evaluation process typically involves a thorough psychiatric assessment, a review of previous treatment history, and medical screening to rule out contraindications.
One of the most compelling aspects of Spravato is how quickly it can begin to lift depressive symptoms. In clinical trials, many patients reported measurable improvement within 24 hours of their first treatment. This rapid onset is especially important for patients in acute crisis or those who have spent years waiting for a medication to work.
The standard treatment schedule begins with twice-weekly dosing for four weeks, followed by weekly dosing for another four weeks, and then transitioning to once weekly or once every two weeks as maintenance. The cumulative effect tends to build over time. Patients who see early improvement are more likely to sustain that progress, while others may need the full induction period before noticing significant change.
It’s worth noting that response is not the same as remission.
Response means a meaningful reduction in symptoms – typically a 50% or greater decrease in depression rating scores.
Remission means symptoms have largely resolved. Both outcomes are meaningful, and both are tracked in the clinical literature.
A common question from patients and families is how Spravato compares to IV ketamine infusions, which have been used off-label for depression for years. Both treatments target the glutamate system, but there are important practical and clinical differences.
Administration: IV ketamine is delivered intravenously over 40 minutes; Spravato is a nasal spray used in a clinical setting
FDA status: Spravato is FDA-approved specifically for depression; IV ketamine is used off-label, meaning the FDA has not cleared it for this purpose
Cost and access: Spravato has a clearer path to insurance reimbursement due to its approved status
Monitoring requirements: Both require on-site monitoring, but Spravato’s protocols are standardized through the REMS program
Efficacy data: Direct head-to-head trials are limited, but both show similar mechanisms and comparable response rates in the literature
For many patients, the FDA-approved status of Spravato and its potential for insurance reimbursement make it the more practical first step compared to IV infusions.
Success rates and clinical data only tell part of the story. The broader mental health picture matters enormously when evaluating Spravato’s value for any individual patient. People living with treatment-resistant depression often carry years of disappointment, failed treatments, and eroding hope. Even partial improvement in mood and function can have profound effects on relationships, employment, and quality of life.
Spravato is not a cure, and it works best as part of a comprehensive treatment plan that may include psychotherapy, lifestyle changes, social support, and ongoing psychiatric care. Patients who engage with therapy alongside Spravato treatment tend to report better long-term outcomes than those relying on the medication alone.
The most commonly reported side effects include:
Dissociation: A feeling of unreality, detachment, or perceptual disturbance – reported in up to 61% of patients but typically resolves within two hours
Dizziness and nausea: Common in early treatment sessions
Sedation: Most patients feel drowsy after dosing, which is why driving after a session is prohibited
Increased blood pressure: This is one of the more medically significant concerns
The issue of increased blood pressure deserves particular attention. Spravato can cause a temporary but notable spike in blood pressure, typically peaking around 40 minutes after administration. Patients with uncontrolled hypertension or a history of cardiovascular disease need to be carefully evaluated before starting treatment. Blood pressure is routinely monitored during every session as part of the REMS safety protocol.
One of the real-world barriers to Spravato access is cost. Without coverage, a single session can cost several hundred dollars, and the initial induction phase alone involves eight sessions. Fortunately, insurance coverage for Spravato has expanded considerably since its approval.
Most major commercial insurers and Medicare now cover Spravato for qualifying patients, though prior authorization is almost always required. Janssen, the manufacturer, also offers a patient assistance program for uninsured or underinsured patients. The key to navigating coverage is working with a prescribing provider who has experience submitting the necessary documentation to demonstrate medical necessity.
I
Finding the right provider is one of the most important steps toward accessing effective care, and our online directory makes that process straightforward. Whether you are dealing with severe depression that has not responded to standard medications or struggling with anxiety symptoms that compound your daily functioning, our healthcare providers are experienced in evaluating whether Spravato is right for you. Because Spravato nasal spray can only be administered in certified clinical settings, working with a specialist who understands the full protocol – from risk evaluation and proper dosing to long-term monitoring – is essential.
Many patients notice symptom relief within the first few sessions. When an adequate dose is established and continued treatment is maintained on schedule, rapid improvement becomes a realistic goal rather than a distant hope. Our directory connects you directly with depression treatment centers that meet the required safety standards and have dedicated teams ready to guide you through every stage of your Spravato journey.
For anyone living with major depressive disorder (MDD) who has exhausted prior medications without lasting relief, Spravato offers a genuinely different path forward. Research in clinical psychopharmacology continues to support its ability to manage treatment-resistant depression, with studies showing that patients treated in structured programs achieved a significant reduction in depression severity compared to placebo. The drug’s established safety profile – built on years of data from certified settings – means that most adverse events are predictable, manageable, and temporary. Patients who complete their full course of Spravato treatment sessions rather than choosing treatment discontinuation prematurely are far more likely to experience significant improvement in their current depressive episode and sustain it over time.
Ultimately, Spravato is not a solution for everyone, and it works best when integrated into a broader care plan that addresses the full complexity of major depression. Under proper medical supervision, and especially for those who have seen little benefit from other treatments, worsening depression symptoms no longer have to feel inevitable. Patients achieved meaningful, measurable results in clinical trials – and those same outcomes are possible in real-world care settings when the right provider, protocol, and support system are in place.
